Healthcare Investment Profiles

The forecast rests on Zacks' Earnings ESP, which compares the Most Accurate Estimate with the Zacks Consensus Estimate. Zacks says stocks with a...

OPKO's continuing operations improved in Q3. Revenue rose 16% to $65.4 million, and the global products segment returned to operating income of $6...

Vir's third-quarter net loss narrowed to US$96.25 million, and nine-month losses of US$141.87 million were also smaller. The source reads this as cost...

Legend Biotech's ASH 2026 abstracts span two very different evidence stages.

• CARVYKTI durability: CARTITUDE-4 subgroup data show durable outcomes...

CVS Health has announced its intent to separate into two public companies, a plan that remains subject to conditions.

• Healthcare solutions arm:...

PPD describes its biotech CRO offering as a way to simplify drug development for small to mid-sized sponsors, covering phases from pre-clinical...

Madrigal is focused on novel therapeutics for MASH, a serious liver disease that can lead to cirrhosis, liver failure, liver cancer, transplant, or...

Elevance Health is one of the leading U.S. health insurers, providing medical benefits to 45 million medical members at the end of 2025.

• Scale: The...

The article projects the digital health market rising from USD 444.6 billion in 2026 to USD 1,690.8 billion by 2035. It points to two policy...

Pfizer's revenue was flat at $16.6 billion against $16.7 billion a year earlier, so newer products are carrying the growth story while COVID sales...

• A former CIA officer, Pacific Research Institute economists, and industry groups say Treasury's proposed biotech restrictions under the COINS Act...

The 3.34% gain on Nov 4 came with heightened intraday volatility. The article ties the move mainly to fundamentals: core EPS topping consensus with...

CVS plans to separate into two companies, expected to close in 2028, unwinding mergers that brought together its retail, Aetna and Caremark...

Nurix shares fell over 30% after Sanofi dropped its STAT6 degrader, but Truist and Leerink point to asset-specific reasons rather than a target...

The author agrees Obamacare is at least partly responsible for high costs, though medicine was costly before the ACA. Key points:

• Premiums: A...

Ocugen's latest update centers on its OCU400 program and its funding runway.

• Bahamas: The LARTA Board granted provisional approval and priority...

Creative Solutions in Healthcare is taking an in-house route to AI. Its dedicated AI team identifies opportunities, develops custom automations, and...

• Earnings: A dozen big pharma companies reported Q3 results. Pfizer's revenue was flat but beat expectations, while Lilly's tirzepatide earned more...

Ultragenyx is laying off 20% of its workforce and dropping programs to cut its annual R&D budget to half of its 2025 spending. It aims to be...

A market research report projects the generative AI in healthcare market will grow from USD 3.3 billion in 2025 to USD 39.8 billion by 2035.

-...